Developments and Recent Trends in Cell and Gene Therapies for Cancer is a comprehensive and strategic reference that explores the scientific foundations, clinical applications, and commercial success of FDA-approved cell and gene therapies. Each chapter focuses on a specific FDA-approved cell or gene therapy product, detailing its development journey, mechanism of action, therapeutic indications, clinical outcomes, regulatory approval, visual data (minimum 4 figures and 3 tables per chapter) and real-world outcomes. The therapies span a wide range of modalities including CAR-T cells, cord blood-derived products, gene editing technologies, and viral vector-based treatments. The chapters are authored by subject matter experts from academia, clinical institutions, and industry, ensuring authoritative and up-to-date content. With contributions from leading experts in academia and industry, the book highlights innovations in CAR-T, cord blood, and gene editing technologies, featuring therapies from companies such as Bristol-Myers Squibb, Pfizer, and Janssen. Designed with modular chapters and rich visual content, it serves both as a scientific resource and a practical guide for oncologists, researchers, biotech professionals, and regulatory stakeholders navigating the evolving landscape of cancer treatment.
- Focuses on a single FDA-approved therapy, offering a consistent and detailed format that includes development history, mechanism of action, clinical indications, and outcomes-making it easy for readers to find targeted, actionable insights
- Bridges foundational science with commercialization pathways, regulatory considerations, and translational challenges-ideal for both researchers and biotech professionals
- Ensures authoritative content and diverse perspectives, enhancing its value as a reference for oncology, drug development, and policy-making
